Sign in

    Boris Tolkachev • Freedom Broker

    Boris Tolkachev is an Analyst at Freedom Broker, focusing on company research and investment analysis within the financial sector. He has participated in corporate events such as the Achieve Life Sciences Q3 2024 earnings call, indicating his coverage extends to companies in life sciences and potentially related sectors. Tolkachev’s earlier career spanned various roles including analyst, broker, manager, and Vice President of the Equities Department at MDM Bank and InkomBank from 1991 to 1999, before joining Freedom Broker. He possesses substantial experience in equity markets, though there is no public information confirming FINRA registration or specific securities licenses, nor quantitative performance metrics or awards.

    Boris Tolkachev's questions to INmune Bio Inc (INMB) leadership

    Boris Tolkachev's questions to INmune Bio Inc (INMB) leadership • Q2 2025

    Question

    Boris Tolkachev of Freedom Broker asked about the Kordstrom BLA submission, specifically whether the ongoing statistical analysis would provide new insights and for details on the planned post-BLA open-label trial.

    Answer

    Chief Scientific Officer Mark Lowdell explained that the new statistical analysis plan is a significant improvement and is likely to identify stronger data to support the MAA and BLA submissions. He clarified that the open-label trial is planned to begin after the BLA submissions, likely in early 2027, and its data would not be part of the initial package, as they believe the data from the current crossover trial is adequate for filing.

    Ask Fintool Equity Research AI

    Boris Tolkachev's questions to Achieve Life Sciences Inc (ACHV) leadership

    Boris Tolkachev's questions to Achieve Life Sciences Inc (ACHV) leadership • Q2 2025

    Question

    Boris Tolkachev of Freedom asked about expectations for updates on the future clinical development roadmap and whether any interim results from the ORCA-OL trial would be shared ahead of a full publication.

    Answer

    President & CMO Dr. Cindy Jacobs stated that the full ORCA-OL study database is expected to be locked by the end of the year, with plans to present the complete data at conferences in 2026 rather than releasing interim results. CEO Rick Stewart emphasized the value of the one-year exposure data, noting the tolerability profile appears consistent with Phase 3 trials and that the company is eager to see the long-term efficacy results.

    Ask Fintool Equity Research AI

    Boris Tolkachev's questions to Achieve Life Sciences Inc (ACHV) leadership • Q4 2024

    Question

    Boris Tolkachev asked about the company's expectations for the effect size in the upcoming Phase III vaping study (ORCA-V2), given the relatively high placebo effect observed in the Phase II ORCA-V1 trial, and whether the FDA had raised questions about this.

    Answer

    Chief Medical Officer Dr. Cindy Jacobs explained that the ORCA-V1 results were instrumental in designing the Phase III trial. The ORCA-V2 study is powered at over 90% with approximately 800 subjects to accommodate the potential for a higher placebo rate, ensuring the trial is not underpowered. She noted that higher placebo rates were also seen in smoking cessation trials two decades ago, so this was anticipated.

    Ask Fintool Equity Research AI

    Boris Tolkachev's questions to Achieve Life Sciences Inc (ACHV) leadership • Q3 2024

    Question

    Boris Tolkachev of Freedom Broker asked for clarification on why ORCA-OL enrollment was completed with fewer than the initially planned 650 patients and inquired about the risk of patient discontinuation and the strategies to maintain engagement.

    Answer

    Dr. Cindy Jacobs, President and Chief Medical Officer, clarified that 650 was a maximum target and enrollment was capped below 500 because the early discontinuation rate was very low, providing confidence in meeting data requirements. She added that retention programs are in place across all trial sites and are proving effective, with the discontinuation rate remaining very low.

    Ask Fintool Equity Research AI